- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06050291
Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe
January 20, 2024 updated by: NewAmsterdam Pharma
A Study to Assess the Effect of Food on the Bioavailability of Obicetrapib and Ezetimibe After Administration of a Fixed-Dose Combination Formulation of Obicetrapib/Ezetimibe, 10 mg/10 mg in Healthy Adult Subjects
This study will assess the effect of food on the bioavailability of obicetrapib and ezetimibe after a single-dose administration of a fixed-dose combination formulation of obicetrapib/ezetimibe, 10 mg/10 mg in healthy adult male and female subjects under fasted and fed conditions.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, single-dose, randomized, two-treatment, two-period, two-sequence crossover relative bioavailability study under fasted and fed conditions.
It will assess the effect of food on the bioavailability of obicetrapib and ezetimibe after a single-dose administration of a fixed-dose combination formulation of obicetrapib/ezetimibe, 10 mg/10 mg in healthy adult male and female subjects under fasted and fed conditions.
The screening period will be up to 28 days.
Patients that are eligible will enter the clinical facility at least 10.5 hours prior to dosing.
Depending on their randomization patients will be fed or fasted prior to dosing.
They will remain confined for at least 24 hours.
After leaving confinement, patients will return to the clinic 9 times for blood draws.
At least 56 days after the first dosing, patients will return to the clinic and go through the same process.
Those previously fed before dosing will be fasted and those previously fasted will be fed.
Patients will return 9 times after their second confinement for additional blood draws.
Study Type
Interventional
Enrollment (Estimated)
28
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Linda Angeline
- Phone Number: 702.435.3902
- Email: info@novumprs.com
Study Locations
-
-
Nevada
-
Las Vegas, Nevada, United States, 89121
- NOVUM
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Key Inclusion Criteria:
- Males and Females aged 18 to 65.
- Body Mass Index (BMI) of 18.5-29.9 kg/m², inclusive.
- Females of childbearing potential must be willing to use approved method of birth control.
- Blood pressure 90/60 - 140/90 mmHg, inclusive.
- Hemoglobin level above lower limit of normal.
- Good health.
Key Exclusion Criteria:
- Females who are pregnant, lactating or likely to become pregnant during the study.
- History of allergy, sensitivity to obicetrapib, ezetimibe or any components of the study products, or history of any drug hypersensitivity or intolerance that may compromise the safety of the subject.
- Significant history or current evidence of chronic infectious disease, system disorders, organ dysfunction especially hypothyroidism, renal or hepatic disorders, cardiovascular disorders, respiratory disorders, diabetes or obesity.
- Clinically significant history or presence of gastrointestinal disease or history of malabsorption within the last year.
- History of psychiatric disorders occurring within the last two years that required the subject to be hospitalized or treated with medication.
- Presence of a medical condition requiring regular treatment with prescription drugs.
- Use of statins, cyclosporine, fibrates (e.g., fenofibrate), bile acid seuqstrants (e.g., cholestyramine), or coumarin anticoagulants within 30 days before initial dosing.
- Use of pharmacologic agents known to significantly induce or inhibit drug-metabolizing enzymes (especially inducers and inhibitors of CYP3A4) within 30 days before initial dosing.
- Use of any drug that can alter the absorption of other drugs by affecting gastrointestinal motility or by changing the gastric pH, in the opinion of the Investigator, within 14 days before initial dosing.
- Use of any drug that can increase or decrease the metabolism and excretion of the study drug, within 14 days before initial dosing.
- Receipt of any drug as part of a research study within 30 days before initial dosing.
- Previous participation in a research study with obicetrapib.
- Drug or alcohol addiction requiring treatment in the 12 months before initial dosing.
- History of excessive alcohol consumption (on average more than 14 units of alcohol/week) during the past 12 months.
- Donation or significant loss of whole blood (480 mL or more) within 30 days or plasma within 14 days before initial dosing.
- Positive test results for HIV, Hepatitis B surface antigen, or Hepatitis C antibody.
- Positive test results for drugs of abuse at screening.
- If female, has a positive pregnancy test at screening.
- Use of tobacco- or nicotine-containing products within 30 days before initial dosing.
- Difficulty swallowing tablets or capsules whole.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FDC Tablet Fed + Fast
Participants will receive a single Obicetrapib/Ezetimibe, 10 mg/10 mg FDC Tablet in a fed condition on Day 1 of treatment followed by a single Obicetrapib/Ezetimibe, 10 mg/10 mg FDC Table in a fasted condition after, at a minimum, a 56 day washout.
|
Obicetrapib/Ezetimibe FDC tablet
|
Experimental: FDC Tablet Fast + Fed
Participants will receive a single Obicetrapib/Ezetimibe, 10 mg/10 mg FDC Tablet in a fasted condition on Day 1 of treatment followed by a single Obicetrapib/Ezetimibe, 10 mg/10 mg FDC Table in a fed condition after, at a minimum, a 56 day washout.
|
Obicetrapib/Ezetimibe FDC tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax
Time Frame: 528.00 hours
|
Maximum measured plasma concentration following each treatment.
|
528.00 hours
|
AUC0-t
Time Frame: 528.00 hours
|
Area under the plasma concentration versus time curve from time zero to the time of the last measurable plasma concentration, as calculated by linear trapezoidal method.
|
528.00 hours
|
AUC0-∞
Time Frame: 528.00 hours
|
Area under the plasma concentration versus time curve from time zero to infinity where AUC0-∞ = AUC0-t + Ct/λz.
Ct is the last measurable concentration and λz is the terminal rate constant.
|
528.00 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tmax
Time Frame: 528.00 hours
|
Time of the maximum measured plasma concentration.
If the maximum value occurs at more than one time point, Tmax is defined as the first time point with this value.
|
528.00 hours
|
Tlag
Time Frame: 528.00 hours
|
Time delay in achieving Tmax
|
528.00 hours
|
λz
Time Frame: 528.00 hours
|
First order rate constant associated with the terminal (log-linear) portion of the curve.
|
528.00 hours
|
t½
Time Frame: 528.00 hours
|
The terminal half-life will be calculated as ln(2)/λz.
|
528.00 hours
|
CL/F
Time Frame: 528.00 hours
|
Apparent oral systemic clearance, calculated as Dose/AUC0-∞
|
528.00 hours
|
Vd/F
Time Frame: 528.00 hours
|
Apparent volume of distribution during terminal phase, calculated as Dose/(AUC0-∞ × λz)
|
528.00 hours
|
R2 adjusted
Time Frame: 528.00 hours
|
Goodness of fit statistic for the terminal phase, adjusted for the number of points used in the estimation of λz.
|
528.00 hours
|
AUC_%Extrap_obs
Time Frame: 528.00 hours
|
The residual area in percentage will be determined by the formula, [(AUC0-∞-AUC0-t)/AUC0-∞] × 100.
|
528.00 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 20, 2024
Primary Completion (Estimated)
April 1, 2024
Study Completion (Estimated)
April 1, 2024
Study Registration Dates
First Submitted
September 17, 2023
First Submitted That Met QC Criteria
September 17, 2023
First Posted (Actual)
September 22, 2023
Study Record Updates
Last Update Posted (Estimated)
January 23, 2024
Last Update Submitted That Met QC Criteria
January 20, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OBEZ-103
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteer Study
-
Atea Pharmaceuticals, Inc.RecruitingHealthy Volunteer StudyUnited States
-
BenevolentAI BioCompletedHealthy Volunteer StudyUnited Kingdom
-
Atea Pharmaceuticals, Inc.Completed
-
Atea Pharmaceuticals, Inc.Completed
-
Atea Pharmaceuticals, Inc.Hoffmann-La RocheCompletedHealthy Volunteer StudyCanada
-
Reckitt Benckiser Healthcare (UK) LimitedSimbec ResearchCompletedHealthy Volunteer Study
-
Orion Corporation, Orion PharmaCompleted
-
Atea Pharmaceuticals, Inc.Not yet recruiting
-
Comanche BiopharmaRecruiting
Clinical Trials on Fixed-Dose Combination (FDC) Tablet
-
Janssen-Cilag S.p.A.CompletedHuman Immunodeficiency Virus (HIV)Italy
-
University of Western Ontario, CanadaPfizerCompleted
-
International Union Against Tuberculosis and Lung...United States Agency for International Development (USAID)UnknownTuberculosisAlgeria, Bolivia, Colombia, Guinea, Mozambique, Nepal, Peru, Tanzania, Vietnam
-
Duke UniversityGilead SciencesCompletedHeart Failure | Pulmonary Disease, Chronic Obstructive | Hepatitis C, Chronic | Lung Diseases, InterstitialUnited States
-
Shandong Suncadia Medicine Co., Ltd.Active, not recruiting
-
Melanoma Institute AustraliaBristol-Myers SquibbRecruiting
-
Rockefeller UniversityNational Institute on Drug Abuse (NIDA)Completed
-
Bristol-Myers SquibbCompleted
-
Fakultas Kedokteran Universitas IndonesiaRecruitingAnti-Tuberculous Drug Reaction | Tuberculous Uveitis | Tuberculosis; Uveitis (Manifestation)Indonesia
-
University Hospital, GhentCompleted